Spinouts working on ketamine-based therapeutics, regenerative medicines for dogs and better sleep are among those that caught our eye this month.

These are the spinouts that caught our eye over the past month. Here's why they should be on your radar, too.

Launched just a year ago to build on work at Weill Cornell Medicine and New York-Presbyterian Hospital, Cleerly has now closed an oversubscribed series C round.

Cambridge Enterprise has put cash into CardiaTec Biosciences in a pre-seed round that marks the inaugural deal for Laidlaw Scholars Ventures.

UT Southwestern Medical Center spinout ReCode Therapeutics has now raised a total of $200m in its series B round from investors including Osage University Partners.

Osage University Partners has added MicroTransponder to a small but mightly portfolio of medical device companies.

Ascenion and Goethe University Frankfurt are among the initiators of Carma Fund I, which will help start up and fund early life science projects.

Chalmers spinout Elypta is working on a metabolism-based liquid biopsy for early cancer detection that it hopes will catch any type of the disease.

Orphan CNS therapy developer Minoryx Therapeutics closed a $54.8m series C and MIT's The Engine co-led a $10.5m seed round for Foundation Alloy.